HYTN and SNDL to Collaborate on GMP-Compliant Vape Cartridge Developmentfor Global Markets
Source: HYTN Innovations Inc.
January 21, 2025 19:30 ET
HYTN and SNDL to
Collaborate on GMP-
Compliant Vape Cartridge
Development for Global
Markets
VANCOUVER, British Columbia, Jan. 21, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE:
HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a company specializing in
pharmaceutical-grade cannabis manufacturing, is pleased to announce that it has entered into a
collaboration agreement (the Agreement) with SNDL Inc. (NASDAQ: SNDL) ("SNDL"), one of the
world’s largest vertically integrated cannabis companies, to jointly develop Good Manufacturing
Practices (GMP) compliant vape cartridges.
Leveraging HYTN’s GMP-certied facility and expertise in quality system development, SNDL will
provide specialized equipment, cannabis consumables, and the required capital to meet stringent
regulatory requirements for GMP product development. HYTN will endeavour to amend its licenses
and/or certicates, establish a stability program, and implement GMP-compliant processes tailored
for vape cartridge production. This initiative follows the Company’s January 10, 2025, announcement
of a manufacturing partnership and initial purchase order with SNDL.
“HYTN holds both a Drug Establishment License and EU GMP equivalent certication under the
International Pharmaceutical Cooperation Scheme (PIC/S), making it one of the few facilities in
Canada capable of manufacturing vape cartridges for international distribution,” stated Jason
Broome, HYTN’s Chief Operations Ofcer. “This collaboration with SNDL is expected to provide the
resources required to rapidly amend our manufacturing systems and deliver vape cartridges to
pharmaceutical markets.”
Under the Agreement which was signed January 17, 2025, neither HYTN nor SNDL are obligated to
exclusivity. While key milestones include the processing of three (3) commercial batches, there is no
obligation regarding sales volume or pricing terms. Upon completion of the development phase,
both parties may explore a commercial manufacturing agreement for vape cartridges.
The market for GMP-compliant cannabis vape products continues to expand. The number of
medical cannabis patients in the UK is projected to increase by 124% from 2024 - 2028¹, and the
German cannabis vape market is expected to reach 966.6 million USD by 2030², with Canada
accounting for approximately 50% of Germany’s medical and scientic cannabis imports. These
trends underscore HYTN’s strategic focus on GMP manufacturing to meet evolving international
requirements.
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical company that specializes in the formulation,
manufacturing, marketing, and sale of products containing psychoactive and psychotropic
compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is
dedicated to becoming a premier provider of these products across all federally regulated markets.
The Company accomplishes this by strategically identifying market opportunities and effectively
bringing innovative products to market through its advanced development platform.
About SNDL Inc.
SNDL is a public company whose shares are traded on the Nasdaq under the symbol "SNDL." SNDL
is the largest private-sector liquor and cannabis retailer in Canada with retail banners that include
Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, and Superette. SNDL is a
licensed cannabis producer and one of the largest vertically integrated cannabis companies in
Canada specializing in low-cost biomass sourcing, indoor cultivation, product innovation, low-cost
manufacturing facilities, and a cannabis brand portfolio that includes Pearls by Grön, No Future,
Bhang Chocolate, Top Leaf, Contraband, Citizen Stash, Sundial Cannabis, Palmetto, Spiritleaf
Selects, Bon Jak, Versus, Value Buds, Namaste, Re-up, Grasslands and Vacay. SNDL's investment
portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships
throughout the North American cannabis industry. For more information on SNDL, please go
About Good Manufacturing Practices (GMP)
GMP guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that
a manufactured product is safe for human consumption or use. Many countries have legislated that
manufacturers follow GMP procedures and create their own GMP guidelines that correspond with
their legislation.
About Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation
Scheme (PIC/S)
The Pharmaceutical Inspection Co-operation Scheme (PIC/S) is a global initiative aimed at
standardizing Good Manufacturing Practices (GMP) across its 56 member countries, thereby
facilitating international trade in pharmaceuticals. Established to ensure the quality and safety of
medicines for human and veterinary use, PIC/S promotes harmonized GMP standards and mutual
recognition of inspection results among regulatory authorities, streamlining the approval process
for pharmaceutical manufacturers.
For more information contact:
Elliot McKerr
Chief Executive Ofcer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
1. Prohibition Partners. (2024). UK's medical cannabis boom: Patients, demand, and consumption surge to all-time highs
– With a record number of private clinics. Article.
2. Lamers, M. (2024). German cannabis imports rise to 34.6 tons as cultivators eye the end of the quota system. Article.
Forward Looking Information Disclaimer
This news release contains statements and information that constitute “forward-looking
information” within the meaning of applicable securities laws. Such information is based on current
expectations, estimates, forecasts, projections, beliefs and assumptions made by management of
the Company. Forward-looking information may include nancial and other projections, as well as
statements regarding future plans, strategies, prospects, objectives or economic performance, or
the assumption underlying any of the foregoing. In some cases, forward-looking statements can be
identied by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “potential”, “anticipate”,
“believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other
similar expressions concerning matters that are not historical facts. Examples of such statements
within this news release include but are not limited to the expectation that SNDL will provide the
Company with the resources required to manufacture and market vape cartridges; the anticipated
demand for vape cartridges; and the ability of the Company to produce vape cartridges and obtain
any or all required regulatory approvals.
Forward-looking information is based on current expectations, assumptions, estimates, forecasts,
projections, analysis and opinions of management made considering its experience and its
perception of trends, current conditions and expected developments, as well as other factors that
management believes to be relevant and reasonable in the circumstances at the date that such
statements are made, but which may prove to be incorrect. The material factors and assumptions
used to develop the forward-looking information contained in this news release include, but are not
limited to: regulatory requirements being obtained and maintained; general business, economic
and political conditions; the Company’s ability to successfully execute its plans and intentions; the
availability of nancing on reasonable terms; the Company’s ability to attract and retain skilled staff;
market competition; the products and technology offered by competitors; and that good
relationships with service providers and other third parties will be established and maintained.
Forward-looking information involves known and unknown risks, uncertainties and other factors
that may cause the actual results, performance or achievements of the Company to differ materially
from any future results, performance or achievements expressed or implied by the forward-looking
information, including, without limitation the Company’s limited operating history; negative cash
ow; nancial position and results of operations differing materially from expectations; the
expectation of incurring future losses and never becoming protable; requiring additional capital to
continue operations; reliance on the third-party service providers; strong competition from
competitors; regulatory changes that may adversely affect the Company; and other risk factors
described in the Company’s regulatory lings. Accordingly, readers should not place undue reliance
on any such forward-looking information. Further, any forward-looking information speaks only as
of the date on which such statement is made. New factors emerge from time to time, and it is not
possible for the Company’s management to predict all such factors and to assess in advance the
impact of each such factor on the Company’s business or the extent to which any factor, or
combination of factors, may cause actual results to differ materially from those contained in any
forward-looking information. The Company does not undertake any obligation to update any
forward-looking information to reect information or events after the date on which it is made or to
reect the occurrence of unanticipated events, except as required by law, including securities laws.
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this
release.
